Immatics Biotechnologies GmbH entered into a definitive business combination agreement with Arya Sciences Acquisition Corp.

The new global pharmaceutical company combines Mylan N.V. with Upjohn, Pfizer Inc.’s off-patent branded and generic established medicines business.